AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00509860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 16 mg/m2 by vein Daily Over 1 Hour x 5 Days
Study NCT02156284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic behaviour by nurses
Description: Control group: patients without specific empathic behaviour~Intervention group: patients who received the empathic behaviour was performed by a trained nurse.
Study NCT04053400 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Study NCT01728701 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (NS)
Description: Normal saline
Study NCT04171596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary care coordination
Description: A registered nurse currently employed at Duke Integrative Medicine, who is also trained as an integrative health coach, will serve in the PCC role. The intervention will flow as follows:~The PCC will call study participants every 2 months during the 6 months (more frequently as needed) for a semi-structured phone check-in, and will track the intervention through the REDCap database. The PCC will use guiding questions to frame the call, but will also:~Respond Ask follow-up questions Provide suggestions that are guided by the patient response and appropriateness to the individual situation and needs and scope of practice.~Prior to the call, the PCC will review the patient chart to see if any outstanding orders, medical visits due, and review the patient health goals (known as the pre-work).~The PCC will call the patient to provide intervention. If patient is not available, the PCC will leave a message, or contact via MyChart to see about scheduling a time to talk.
Study NCT00890006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced imaging for radiotherapy planning and guidance
Description: Integration of MRI in the treatment planning process / Integration of daily cone-beam computed tomography (CBCT)
Study NCT00664976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Description: Electroconvulsive therapy
Study NCT00664976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
Study NCT06000514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sm29 Protein, Schistosoma Mansoni
Description: Sm29 cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
Study NCT06000514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentavalent antimony (Sbv)
Description: Placebo cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
Study NCT06000514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentavalent antimony (Sbv)
Description: Placebo cream twice a day in the ulcer(s), during 20 days; and Systemic IV Pentavalent antimony (Sbv) at 20mg/kg/day during 20 days.
Study NCT00512707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (open label)
Description: On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
Study NCT00512707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil citrate (open label)
Description: On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
Study NCT00512707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
Study NCT00512707 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: 3 tubes of placebo gel equivalent to the amount of the testosterone gel will be applied during the placebo-controlled testosterone gel intervention for 16 weeks..
Study NCT01829334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART dental sealant
Description: ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
Study NCT01829334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin dental sealant
Description: Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
Study NCT01829334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium fluoride varnish
Description: Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
Study NCT01829334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver fluoride solution
Description: Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
Study NCT03174236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
Study NCT04444778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive airway pressure
Study NCT03174236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzyl penicillin
Description: The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
Study NCT03174236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials.
Study NCT03174236 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension manufactured to match metronidazole
Study NCT03174236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
Study NCT03965910 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Demonstration the Importance of Early Rehabilitation in Stroke Patients Based on Diffusion Tensor Imaging Data
Description: Twenty-eight stroke patients aged 36-72 years admitted to the our Physical Medicine and Rehabilitation Outpatient Clinics were included in this prospective study. After the approval of the ethics committee, written informed consent was obtained from the patients after they were informed about the content and purpose of the study, the schedule of rehabilitation to be administered, and the features of cranial magnetic resonance imaging (MRI) to be performed. Patients with confirmed diagnosis of stroke by computed tomography and/or MRI techniques were randomized into two groups according to the onset of post-stroke rehabilitation. The patients were randomized according to the duration of their admission to our clinic for rehabilitation. Group 1 consisted of patients admitted to our clinic within 1-4 weeks after stroke; Group 2 consisted of patients admitted within 5-8 weeks after stroke.~Late initiation of rehabilitation in Group 2 patients is not a condition related to our clinic.
Study NCT00680667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coriolus versicolor extract
Description: Trametes versicolor (Tv) capsules at the assigned dose level (3 grams/day up to 24 grams/day) twice a day every day and continuing for weeks.
Study NCT04271605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and exercise suggestion
Description: diet and exercise suggestion according to blood biochemistry data and bone mineral density
Study NCT02642289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Description: Probiotic 5000, a commercial probiotic product provided by the company Complementos Fitonutricionales, S.L.
Study NCT02642289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosus GG ®
Description: Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab Laboratorios Nutergia
Study NCT02642289 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Innocuous substance
Study NCT02387853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100
Study NCT04648956 — intervention group
Intervention type: OTHER
Intervention: Standard treatment
Description: Participants shall fill the ICOAP-Ar questionnaire three times within one month in addition to other questionnaires including the KOOS/HOOS, and the Global Rating of Change Scale (GRoC). The first two times will be within a time frame of 48-72 hours. The third time will be after one month.
Study NCT02309879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
Study NCT02309879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine infusion
Description: Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
Study NCT03979014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasill 9™ vaccine
Description: 3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month
Study NCT04664972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel +doxorubicin+ cyclophosphamide
Description: The control group was treated with TAC (docetaxel 75 mg / m2 + adriamycin 50 mg / m2 + cyclophosphamide 500 mg / m2) for 6 cycles, 21 days was a cycle.
Study NCT04664972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel +Cisplatin
Description: The experimental group was treated with TP (docetaxel 75mg/m2 day 1 + cisplatin 25 mg/m2 day 1,2,3) neoadjuvant chemotherapy for 6 cycles, 21 days as a cycle.
Study NCT01719874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCN-032
Study NCT01719874 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Study NCT04415307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture over acupoints.
Study NCT04415307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Far-Infrared heat-patch attachment
Description: Far-Infrared heat-patch attachment over acupoints.
Study NCT04415307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and Fir-Infrared heat-patch attachment
Description: Acupuncture and Far-Infrared heat-patch attachment over acupoints.
Study NCT04415307 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Far-Infrared heat-patch attachment over acupoints without electric current passing.
Description: Far-Infrared heat-patch attachment over acupoints without electric current passing.
Study NCT02590094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab or intravitreal ziv-aflibercept
Description: Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
Study NCT04376840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample and data record
Description: Blood sample and data record
Study NCT03804021 — intervention group
Intervention type: GENETIC
Intervention: No Intervention
Description: Subjects who received ADVM-043 in a parent study (ADVANCE; NCT02168686)
Study NCT06773429 — intervention group
Intervention type: DRUG
Intervention: E2 Valerate
Description: To experimentally elevate E2 levels females received 6mg of E2 valerate (Progynova21©) on two consecutive days (in total 12mg).
Study NCT06773429 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Placebo pills (blue-colored hard gelatine capsules filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) have been administered for the placebo-controlled condition.
Study NCT01234740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bafetinib
Description: Given orally
Study NCT01234740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microdialysis
Description: Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy
Study NCT01234740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01234740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Description: Correlative studies
Study NCT01234740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study NCT01234740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01234740 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies
Study NCT01234740 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies
Study NCT01234740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01234740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: debulking craniotomy
Study NCT03167112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Patients receive Oxaliplatin 85 mg/m2 over 2 hours.
Study NCT03167112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.
Study NCT03167112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
Study NCT03167112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
Study NCT03161912 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: As per the treating physicians discretion.
Study NCT02363361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Day 1. 800 mg, Day 2-14: 2 \* 400 mg per day
Study NCT03509363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke physiotherapy home exercise video
Description: a set of exercise video with QR code provided in home exercise pamphlets
Study NCT02997553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
Study NCT02997553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium99
Description: Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.~Lymphoscintigraphy is performed to identify the sentinel node
Study NCT02997553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optonuclear probe
Description: The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
Study NCT02997553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quest Camera
Description: The detection of sentinel lymph node will be conducted by a camera able to determine imagery of fluorescence during surgery.
Study NCT03542903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy
Description: Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.~The stimulation dose is determined by titration method, during the first ECT session.~The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.~For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg).
Study NCT01983384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processed EEG-guided anesthetic depth
Description: Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
Study NCT01983384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Processed EEG-guided anesthetic depth
Description: Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
Study NCT02998203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Organic diet
Description: Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
Study NCT01762735 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
Study NCT01762735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water injection
Description: Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
Study NCT04543266 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Resection of tumors
Study NCT02199314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Study NCT01443364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
Study NCT02251834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW)
Description: The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.
Study NCT02251834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care and health education brochures every 4 months.
Description: Patients randomized to the control group will receive usual care.
Study NCT03905239 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: algorithm
Description: clinical examination and procalcitonin assessment
Study NCT01044745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01044745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or PO
Study NCT01044745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV
Study NCT01044745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study NCT01044745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Stem cell transplant
Study NCT01044745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01044745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft versus host disease prophylaxis/therapy
Description: Undergo graft versus host disease prophylaxis/therapy
Study NCT01044745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO or IV
Study NCT01044745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT01044745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV